Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives $56.35 Average PT from Brokerages

Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $56.35.

A number of research analysts recently weighed in on ZLAB shares. Wall Street Zen downgraded shares of Zai Lab from a “buy” rating to a “hold” rating in a research report on Friday, June 27th. Jefferies Financial Group started coverage on shares of Zai Lab in a research report on Monday, August 25th. They issued a “buy” rating and a $52.00 target price for the company. Citigroup reaffirmed a “buy” rating and issued a $69.00 target price (up previously from $66.00) on shares of Zai Lab in a research report on Monday, August 11th. Finally, Leerink Partners set a $75.00 price target on shares of Zai Lab and gave the company an “outperform” rating in a research note on Monday, June 30th.

Insider Activity

In other Zai Lab news, CFO Yajing Chen sold 1,438 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $35.42, for a total value of $50,933.96. Following the completion of the sale, the chief financial officer owned 16,720 shares in the company, valued at $592,222.40. This trade represents a 7.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Rafael Amado sold 3,000 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $35.00, for a total transaction of $105,000.00. Following the completion of the sale, the insider owned 42,178 shares of the company’s stock, valued at approximately $1,476,230. This represents a 6.64% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 215,710 shares of company stock worth $7,589,684. 4.96% of the stock is owned by insiders.

Institutional Trading of Zai Lab

Hedge funds have recently modified their holdings of the stock. Oppenheimer Asset Management Inc. acquired a new stake in shares of Zai Lab during the 1st quarter worth about $603,000. BNP Paribas Financial Markets lifted its stake in shares of Zai Lab by 1,439.8% during the 4th quarter. BNP Paribas Financial Markets now owns 19,755 shares of the company’s stock worth $517,000 after buying an additional 18,472 shares during the last quarter. Raymond James Financial Inc. raised its stake in Zai Lab by 219.6% in the 1st quarter. Raymond James Financial Inc. now owns 125,967 shares of the company’s stock worth $4,552,000 after purchasing an additional 86,547 shares in the last quarter. Northern Trust Corp raised its stake in Zai Lab by 117.8% in the 4th quarter. Northern Trust Corp now owns 49,365 shares of the company’s stock worth $1,293,000 after purchasing an additional 26,700 shares in the last quarter. Finally, Cerity Partners LLC acquired a new stake in Zai Lab in the 1st quarter worth about $420,000. Institutional investors and hedge funds own 41.65% of the company’s stock.

Zai Lab Stock Down 2.7%

Shares of ZLAB stock opened at $31.92 on Friday. The company has a market capitalization of $3.57 billion, a price-to-earnings ratio of -15.65 and a beta of 1.04. Zai Lab has a 12-month low of $20.17 and a 12-month high of $44.34. The firm has a fifty day moving average of $34.71 and a 200-day moving average of $33.98.

Zai Lab (NASDAQ:ZLAB) last released its earnings results on Thursday, August 7th. The company reported ($0.37) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.37). The business had revenue of $109.98 million during the quarter, compared to the consensus estimate of $125.66 million. Zai Lab had a negative net margin of 49.68% and a negative return on equity of 27.32%. Zai Lab has set its FY 2025 guidance at EPS. On average, equities analysts expect that Zai Lab will post -2.58 EPS for the current year.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.